Also known as: molecular glue degraders, molecular glues
Bristol Myers Squibb started a Phase 1 trial of BMS-986506 in clear cell renal cell carcinoma, triggering a $10 million milestone payment to Evotec SE. The candidate is the first molecular glue from the companies’ protein-degradation partnership to enter human testing.
Two Nature Chemical Biology studies described new routes to molecular glue discovery. One identified ZZ1 and YPEL5-linked CTLH recruitment, while another found an ENL degrader in leukemia cells.
Researchers unveil tumor-intrinsic role of PD-L1 in lung cancer progression and develop systematic method for discovering molecular glues that selectively degrade disease proteins, while advances in immunology research aim to improve care for immune-mediated inflammatory diseases.
C4 Therapeutics has initiated its Phase 2 MOMENTUM trial of cemsidomide in relapsed/refractory multiple myeloma, targeting enrollment completion in Q1 2027 and a registrational dataset by 2028. The company plans a combination study with elranatamab in Q2 2026.
Researchers developed a high-throughput method to systematically discover molecular glues that trigger degradation of disease-causing proteins, demonstrating efficacy against a leukemia-associated protein and transforming drug discovery from chance to scalable workflow.
